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Opioid analgesics provide eﬀective treatment for noncancer pain, but many physicians have concerns about adverse eﬀects,
tolerance, and addiction. Misuse of opioids is prominent in patients with chronic back pain and early recognition of misuse risk
c o u l dh e l pp h y s i c i a n so ﬀer adequate patient care while implementing appropriate levels of monitoring to reduce aberrant drug-
relatedbehaviors.Inthisreview,wediscussopioidabuseandmisuseissuesthatoftenariseinthetreatmentofpatientswithchronic
back pain and present an overview of assessment and treatment strategies that can be eﬀective in improving compliance with the
use of prescription opioids for pain. Many persons with chronic back pain have signiﬁcant medical, psychiatric and substance use
comorbidities that aﬀect treatment decisions and a comprehensive evaluation that includes a detailed history, physical, and mental
health evaluation is essential. Although there is no “gold standard” for opioid misuse risk assessment, several validated measures
havebeenshowntobeuseful.Controlledsubstanceagreements,regularurinedrugscreens,andinterventionssuchasmotivational
counseling have been shown to help improve patient compliance with opioids and to minimize aberrant drug-related behavior.
Finally, we discuss the future of abuse-deterrent opioids and other potential strategies for back pain management.
1.Introduction
Chronic back pain negatively impacts every facet of daily liv-
ing. Chronic back pain, deﬁned as pain that lasts longer than
6 months, has been seen to interfere with individual’s quality
oflife,byinterruptingsleep,employment,socialfunctioning,
and many other daily activities. Patients with chronic back
pain typically report feelings of depression, anxiety, irritabil-
ity, sexual dysfunction, and decreased energy. Often chronic
back pain adversely aﬀects family roles and contributes to
worry about ﬁnancial limitations and future disability [1–5].
Studies analyzing factors aﬀecting health and illness have
shown that chronic pain, of which chronic back pain is
the most prominent, is a widespread international problem
[6–8]. More than 90 million Americans show symptoms of
chronic pain, which is approximately one third of the US
population. In the United States, chronic pain accounts for
21% of emergency department visits and 25% of annual
missed workdays. Chronic pain is responsible for up to $100
billioninannualdirectandindirectcosts,makingitthemost
ﬁnancially challenging condition to date [9–12].
Opioid analgesics have been used to help manage acute
as well as cancer-related pain [13]. This class of prescription
medication is also used as a treatment for individuals with
chronic noncancer back pain; however, many physicians are
reluctant to prescribe opioids for these patients since this
medication contributes to adverse eﬀects, tolerance, and
addiction [14].
The National Comorbidity Survey of Psychiatric Dis-
orders collected epidemiological data, indicating a lifetime
prevalence of 7.5% for drug dependence (illicit or prescrip-
tion drugs) and 14.1% for alcohol dependence for individ-
uals in the United States [15]. The Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV) results showed
approximately 3% of US citizens 18 years or older met the
criteria for illicit drug abuse or dependence [16]. Another
study that used a sample of 363 inpatients between the ages2 Pain Research and Treatment
of18to49foundthat21.8%oftheparticipantshadacurrent
addiction to alcohol or illicit drugs [17].
There has been a steady increase in the use of opioids
in the United States [18]. This has been due to increasing
pain awareness, support from pain organizations, changes
in treatment guidelines, increasing patient understanding of
pain,newformulations,andindustrypressure.Itisestimated
that 235 million opioid prescriptions were written in the
United States in 2004 alone [19]. The nonmedical use of
prescription opioids has also continually increased among
all ages, and now prescription opioid analgesics are reported
to be the most frequently abused drugs in the United
States [20]. Misuse of opioids is also prominent in patients
with chronic back pain, and unintentional drug overdose
due to prescription opioids has continued to increase since
1970 (http://www.cdc.gov/HomeandRecreationalSafety/pdf/
(poision-issue-brief.pdf, Accessed 4/16/10). A literature re-
view done by Strain [21] reported that 15% to 23% of
patients with chronic pain met the criteria for a substance
abuse disorder, suggesting that this continues to be a
problem.
The pain literature suggests that physicians are able to
better provide suitable treatment and care to patients with
chronic pain once substance misuse causes are recognized
[22]. Misuse behaviors of prescribed opioid medication are
determined by assessment and treatment protocols. These
protocols help to identify patients who show signs of opioid
misuse, since it provides the clinicians with an overview of
the patient’s background and behavior.
In this paper, we review opioid abuse and misuse issues
that often arise in the treatment of patients with chronic
noncancer back pain and discuss assessment and treatment
strategies that can be eﬀective in improving compliance with
the use of prescription opioids for pain. The intent of this
review paper is to provide a brief overview of studies on the
assessmentandtreatmentofabuseriskonopioidprescribing
for chronic noncancer pain. This paper is not a systematic
review, but rather a critical discussion of current assessment
techniques and procedures within the clinical setting. The
paperisdividedintothefollowingsubsections:(1)deﬁnition
of terms, (2) adverse eﬀects of opioid therapy, (3) medical
comorbidity among pain patients, (4) initial medical assess-
ment, (5) psychiatric comorbitidity, (6) substance abuse
assessment, (7) urine toxicology screens, (8) opioid therapy
agreement, (9) abuse-deterrent opioids, (10) interventions
for high-risk patients, and (11) future considerations.
2. Deﬁnition of Terms
A clear deﬁnition of terms helps to minimize confusion and
toclarifytheobjectivesoftherapywithpatientstakingopioid
analgesics for pain (Appendix A). Substance misuse is the use
of any drug in a manner other than how it is indicated or
prescribed, while substance abuse is deﬁned as the use of any
substance when such use is unlawful or when such use is
detrimental to the user or others. Addiction is a behavioral
pattern of substance abuse characterized by overwhelming
involvement with the use of a drug. Addiction is generally
understood to be a chronic condition from which recovery is
possible;however,theunderlyingneurobiologicdysfunction,
once manifested, is believed to persist [16, 23]. Addiction
focusesoncompulsiveuseofthedrugthatresultsinphysical,
psychological,andsocialharmtotheuser.Anindividualwho
has an addiction to a drug continues to use it, despite harm.
Physical dependence is a common phenomenon of all mam-
mals taking opioids characterized with physical withdrawal
symptoms when an opioid is discontinued. Tolerance is also
a commonly observed phenomenon when taking opioids
over time in which the individual becomes used to the drug
and has a need for increasing doses to maintain the same
eﬀect. Both physical dependence and tolerance are typically
found among patients who use opioids for chronic pain
and are unrelated to true addiction. Finally, aberrant drug-
related behavior is behavior suggestive of a substance abuse
and/or addiction disorder. Examples are selling prescription
drugs, prescription forgery, stealing or “borrowing” drugs
from others, injecting oral formulations, obtaining prescrip-
tion drugs from nonmedical sources, multiple episodes of
prescription “loss,” repeatedly seeking prescriptions from
other clinicians, evidence of deterioration in function (work,
home,andfamily),andrepeatedresistancetochangetherapy
despite evidence of physical and psychological problems.
Several authors have shown that the majority of those
taking opioids for the treatment of pain typically do not
develop addiction or substance use disorders [24], although
most patients on long-term opioid therapy develop physical
dependence and tolerance to the medication. Those who are
undermedicated may demonstrate drug-seeking behaviors
or try and self-manage unauthorized dosage increases in an
attempt to ﬁnd relief. Among many of these patients, once
adequate relief from the pain is obtained, the drug-seeking
behaviors, otherwise known as pseudoaddiction, disappear
[25]. However, the long-term eﬃcacy of opioid therapy has
been questioned and is estimated that less than 40% reach a
35% improvement in pain intensity [26].
3. Adverse Effects of Opioid Therapy
Thereareanumberofadverseeﬀectsassociatedwithchronic
opioid therapy including nausea, sedation, and opioid-
induced bowel dysfunction. There has been a suspected
relationship between opioid therapy and a number of
conditions such as endocrine deﬁciencies [27], dose-related
cardiac arrhythmia [28], and disordered breathing possibly
contributing to unexplained deaths [29]. Despite concerns
regardingtheuseoflong-termopioidtreatmentforpain,few
trials exist assessing their eﬃcacy [30]. One study suggested
that opioids and NSAIDs may aid short-term pain relief in
patients with low back pain; however, stopping treatment
maycauseanincreaseinsymptoms[31].Ithasbeenseenthat
some patients become psychologically dependent after long-
term opioid use [32, 33]. Other patients who are chronically
maintained on high doses of opioids manifest impaired
cognition, problems with psychomotor performance, and
opioid-induced hyperalgesia [34]. Studies also suggest that
a relationship exists between early misuse of opioids and
addiction. This relationship emphasizes the need for earlyPain Research and Treatment 3
detection of risk, close monitoring, and direct interventions
when needed.
4. MedicalComorbidity among Pain Patients
Many patients with chronic severe intractable back pain
may present with several signiﬁcant medical comorbidities
that can aﬀect the course of treatment. Some of the most
common comorbidities include asthma, chronic obstruc-
tive pulmonary disease, diabetes mellitus, coronary artery
disease, hypertension, ulcers, kidney, bladder, and liver
problems, or cancer. When patients are asked to rate their
level of pain, comorbid conditions may contribute to this
rating.
Some individuals suﬀering from chronic back pain have
a history of unhealthy behaviors including minimal exercise,
poor diet, and smoking cigarettes. Over time, they experi-
ence weight gain and deconditioning. Many chronic pain
patients are on multiple medications prescribed by multiple
providers, which include blood thinners, blood pressure
and heart disease medications, inhalers, and antidepressants.
Several chronic pain patients have allergies and reactions
to some medications. They may also have medical devices
implanted and wear prostheses. It is essential for clinicians
to assess and identify current and past medical conditions to
avoid any complications.
5.InitialMedicalAssessment
It should be required for all patients considered for opioid
therapy to undergo an extensive initial evaluation, including
a thorough medical history, review of past medical records, a
urine toxicology screen, and physical examination. For most
patients, a psychological evaluation should be conducted,
including completion of screening questionnaires. The com-
prehensive evaluation process should involve identifying
other controlled substance prescribers. Opioid prescriptions
should only rarely be prescribed to patients on their ﬁrst
visit, and it is important for patients to be informed of
the comprehensive assessment process and the policy not to
prescribe opioids until all information is obtained.
A urine toxicology screen should be obtained at the
ﬁrst visit and compared with the patient’s recent medication
intake in order to identify any opioid misuse. A diagnosis
of the patient’s back pain should be documented to provide
clinicians with the primary pain site and probable cause
of pain. It is essential for all of the patient’s providers to
communicate with one another in order to properly and
eﬀectively manage the patient’s care. It is important for
clinicians to examine several factors, including a patient’s
age and gender, to provide the best clinical assessment and
treatment for the patient. There is evidence to suggest that
younger individuals who are prone to impulsivity have a
greater risk for misuse of opioids [30, 35, 36]. One recent
study of gender diﬀerences and opioid misuse suggested
that women are at greater risk for misusing opioids due
to emotional issues and aﬀective distress, while men tend
to misuse opioids due to legal and problematic behavioral
issues [37]. Assessment of levels of emotionality is impor-
tant and, thus, a psychological assessment would also be
valuable.
6. PsychiatricComorbidity
Many chronic intractable back pain patients report feelings
of depression, anxiety, irritability and have a history of
physical or sexual abuse, or a past history of a mood disorder
[38, 39]. Close to ﬁfty percent of patients with chronic
pain have a comorbid psychiatric condition, and 35% of
patients with chronic back and neck pain have a comorbid
depression or anxiety disorder [40–42]. In surveys of chronic
pain clinic populations, 50% to 80% of patients with chronic
pain had signs of psychopathology, making this the most
prevalent comorbidity in these patients [43–46]. Studies
suggest that most patients with chronic pain present with
some psychiatric symptoms.
One study conducted by Arkinstall and colleagues found
a 50% prevalence of mood disorder in patients who were
prescribed opioids, showing this to be a common diagnosis
for chronic pain patients [47]. Another study found that
physiciansaremorelikelytoprescribeopioidsfornoncancer-
related pain on the basis of increased aﬀective distress and
pain behavior, rather than the patient’s pain severity or
objective physical pathology [43]. It has been found that
patients who have chronic back pain with psychopathology
are more likely to report greater pain intensity, more pain-
related disability, and a larger aﬀective component to their
pain than those who don’t have evidence of psychopathology
[48, 49].
Patients with chronic pain and psychopathology, espe-
cially those with chronic low back pain, typically have
poorer pain and disability outcome from treatments [50–
53]. In studies of patients with both chronic pain and
anxiety and/or depression, there was a signiﬁcantly worse
return to work rate one year after injury compared with
those without any psychopathology [54, 55]. Patients who
had chronic pain with low psychopathology had a 40%
greater reduction in pain with IV morphine than those in a
high-psychopathology group [56]. It becomes apparent that
patientswithahighdegreeofnegativeaﬀectbeneﬁtlessfrom
opioids in an attempt to try and control their pain.
Many patients with substance use disorders also have
aﬀective disorders. Attempting to manage a comorbid
aﬀective disorder may result in decreased substance abuse
behaviors, although they may be at risk of relapse [57–
60]. Hasin and colleagues found some patients abusing
their pain medication as a way to alleviate their psychiatric
symptoms [61]. From this ﬁnding and other reviews, there is
a strong suggestion that individuals with a mood disorder
who self-medicate for negative aﬀect are at increased risk
for substance abuse [62]. Since many patients with chronic
back or neck pain frequently report mood swings and
prominent anxiety and depression symptoms, it remains
important to carefully monitor all patients for psychiatric
comorbidity. A multidisciplinary assessment with input by a
psychiatrist or psychologist would be recommended. In this4 Pain Research and Treatment
way, individuals who self-medicate with opioids for mood
ﬂ u c t u a t i o n sh a v eag r e a t e rc h a n c et ob ei d e n t i ﬁ e d .
7. SubstanceAbuseAssessment
The US Department of Justice recommended eﬀorts to
improve identiﬁcation of abuse and diversion of controlled
substancesby healthcareproviders[63].Physicianscontinue
to struggle with providing the appropriate pain relief for
patients, while minimizing the misuse of opioid analgesics
[64]. Misuse of pain medications includes selling and
diverting prescription drugs, seeking prescriptions from
multiple providers, using illicit drugs, snorting or injecting
medications,andusingdrugsinamannerotherthantheway
it was intended.
There are a variety of assessment measures that can
be used to help identify those patients who are prone to
misuse their pain medications [36]. Structured interview
measures have been published for assessment of alcoholism
and drug abuse based on DSM-IV criteria [65], but these
measures have not been validated in individuals with
chronic pain. Some substance abuse measures, including
the CAGE Questionnaire, Michigan Alcoholism Screening
Test, and Self-Administered Alcoholism Screening Test, were
initially designed for other patient populations [66–68].
Using traditional substance abuse assessment tools may be
beneﬁcialforpatientswithaseveresubstanceabusedisorder;
however, these assessments may not be useful for individuals
with chronic pain since there is a greater chance of a false
positive with these measures. In general, there is a risk
that medication abuse using traditional substance abuse
measures will be identiﬁed based on reports of tolerance and
dependence when no abuse exists. Validated measures most
appropriate for persons with chronic pain are presented in
Appendix B.
The Screener and Opioid Assessment for Patients with
Pain-Revised (SOAPP-R) is a 24-item self-administered
screening tool developed and validated for those persons
with chronic pain who are being considered for long-term
opioid therapy. The SOAPP-R is designed to predict aberrant
medication-related behaviors [69, 70]. This questionnaire
includes subtle items that encourage the patient to admit
to certain factors that are positively correlated with opioid
misuse yet outwardly are not perceived to lead to reprisals.
Any individual who scores more than an 18 on the SOAPP-
R is rated as being at risk for opioid misuse. This screening
tool has been found to identify 90% of those who will
eventually misuse opioids. It has been cross-validated in over
600 patients across the United States. The reliability and
predictive validity of the SOAPP-R, as measured by the area
under the curve (AUC), were found to be highly signiﬁcant
(test-retest reliability = .91; coeﬃcient α = .86; AUC = .74)
and were suﬃciently similar to values found with the initial
sample. A cut-oﬀ score of 18 revealed a sensitivity of .80 and
speciﬁcity of .52. Results of a cross-validation suggest that
the psychometric parameters of the SOAPP-R are not based
solely on the unique characteristics of the initial validation
sample [71].
The Current Opioid Misuse Measure (COMM) is a 17-
item questionnaire developed and validated for patients
who have already been prescribed opioids for chronic pain
[72]. The COMM helps to identify those patients who are
currently misusing their prescribed opioid medication. The
COMM is diﬀerent from other measures that were created to
predict misuse behaviors in patients before being prescribed
opioids. Rather, the COMM was created to repeatedly
document opioid compliance and improve clinician sense
of appropriateness of opioid therapy. The COMM has been
determined to be a brief but useful self-report measure
of current aberrant drug-related behavior. The reliability
and predictive validity in this cross validation, as measured
by the area under the curve (AUC), were found to be
highly signiﬁcant (AUC = .79) and not signiﬁcantly diﬀerent
from the AUC obtained in the original validation study
(AUC = .81). Reliability (coeﬃcient α) was .83, which is
comparable to the.86 obtained in the original sample [72].
Results of a cross validation suggest that the psychometric
parameters of the COMM are not based solely on unique
characteristics of the initial validation sample [73]. Both
the SOAPP-R and COMM include subtle items that are
correlated with opioid misuse and are items patients are
willing to answer honestly.
Other validated measures have also been developed to
screen patients with pain for addiction risk potential. The
5-item Opioid Risk Tool (ORT), a brief checklist completed
by the clinician, is a validated questionnaire that predicts
which patients will display aberrant drug-related behaviors
[68, 74]. Scores of 8 or higher suggest high risk for opioid
medication abuse. A similar rating tool, the DIRE (standing
for diagnosis, intractability, risk, and eﬃcacy), is a clinician-
rating scale used to predict suitability for long-term opioid
treatment for noncancer pain [75]. Scores higher than 14 on
the DIRE suggest a greater suitability of opioid therapy for
patientswithpain.ThePainAssessmentandDocumentation
Tool is yet another scale completed by the clinician, which
provides a detailed documentation of the patient’s progress,
whichalsohelpstoobjectivelyrecordapatient’scare[74,76].
The Screening Instrument for Substance Abuse Potential
(SISAP)isaself-reportscreeningquestionnaireforsubstance
abuse potential based mostly on the alcohol literature [77].
Unfortunately, these measures, other than the SOAPP-R and
COMM, lack cross validation studies. Also, tools to assess
riskofopioidmisusewerevalidatedforpatientswithchronic
pain but were not designed speciﬁcally for patients with
chronic back pain. When using any tools to assess risk of
opioid misuse, it is essential to have detailed background
information about the patient.
It is important to note that scores of any clinical assess-
ment tool used to determine abuse risk are not necessarily
reason to deny opioids, but rather provide an estimate of
the level of appropriate monitoring for the patient. Thus,
although these clinical assessments are useful to estimate
risk of noncompliant opioid use, the results are most useful
to help determine how closely to monitor patients during
opioid therapy.
Patients who are typically at a lower risk for misusing
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have a record of rarely misusing any medication, show stable
mood, are thoughtful and responsible, and generally have an
easy-goingpersonality.Riskfactorsforopioidmisuseinclude
(1) family or personal history of substance abuse, (2) young
age, (3) history of criminal activity and/or legal problems
(e.g.,chargeddrivingundertheinﬂuence,DUI),(4)frequent
contact with high-risk individuals or environments, (5)
history of previous problems with employers, family, and
friends, (6) history of risk-taking/thrill-seeking behavior,
(7) smoking cigarettes, (8) history of severe depression or
anxiety, (9) multiple psychosocial stressors, and (10) pre-
vious drug and/or alcohol rehabilitation (see Appendix C).
Patients prescribed opioids should be monitored regularly
and should be examined for experiencing any adverse
eﬀects. Appropriate follow-up care should include repeated
psychological evaluations.
8.UrineToxicology Screens
Clinicians use urine drug screens in order to closely mon-
itor patient’s adherence to their prescribed opioid med-
ication. Highly sensitive and speciﬁc urine screens (e.g.,
gas chromatography/mass spectrometry—GC/MS) help to
identify presence and quantities of prescription medications,
presence of illegal substances, and/or absence of prescribed
medications. Even though many patients prescribed opioids
do not misuse their medication, it still is important to
document compliance for all patients on chronic opioid
therapy by obtaining a urine screen at least yearly.
The combination of urine screens, self-report question-
naires, and behavioral observation methods has allowed
physicians to properly identify which patients are misusing
their prescribed opioids. One study gathered urine tox-
icology results among 122 patients who were prescribed
opioids for noncancer pain and found abnormal results
in 43% of this sample [78]. Another study found 21% of
the study patients with no obvious behavioral issues to
have either a positive urine screen result for an illicit drug
or a nonprescribed controlled medication. These results
imply that some risk factors for opioid misuse may not
always properly identify patients who do misuse their pain
medication. An additional study of 226 patients primarily
with chronic back pain surprisingly found 46.5% of the
sampletohaveabnormalurinetoxicologyscreenresults[35].
In a retrospective study of 470 patients, 4 of 10 patients pre-
scribed opioids also had abnormal urine toxicology screens
[79]. These studies underscore the importance of urine
toxicology screens along with behavioral observation and
self-report measures to help identify aberrant drug-related
behavior. Although immunoassay urine screens are often
used as the ﬁrst line of analysis, gas chromatography/mass
spectrometry urine screens provide useful results in being
able to quantify the extent of illicit and prescription drug
use. This type of urine toxicology screen is also able to detect
drug metabolites, as well as determine whether the patient
has attempted to adulterate the urine sample.
Increasingly, patients with chronic pain are using mari-
juana for the treatment of their symptoms, and evidence of
THC in the urine has become more prevalent [80]. There is
an ongoing debate about the use of medical marijuana and
speciﬁcally its use among pain patients prescribed opioids
for pain [81]. Some clinicians feel that in order to be
prescribed opioids, there needs to be a record of clean
urinesandthatuseofmarijuanaisunacceptablewhentaking
prescription opioids because of its association with abuse of
other illicit substances. Others feel that use of marijuana is
not grounds for discontinuation of opioid therapy, although
legal implications need to be considered. Nonetheless, the
use of regular use of urine toxicology screens is important
in identifying opioid misuse, and doctor-patient discussions
about how the responsible use of opioids is deﬁned are
essential.
9. Opioid Therapy Agreement
Controlled-substance agreements are frequently used in
clinics to clarify the roles of the patients and providers
and to ultimately improve patient compliance with their
opioid medication. These documented agreements provide
education and mutual consent among patients and providers
and inform patients of their responsibilities when using
prescribed pain medication.
A controlled-substance agreement should state that
the patient is only allowed to remain in the program if
they adhere to the termed conditions (Appendix D). The
following are sample conditions: (1) patients should only use
their prescribed medications as directed by their physician;
(2) they will be unable to receive replacement medication
if lost or stolen; (3) they agree to only receive prescription
pain medication from one physician; (4) they will not
receive additional medication if their prescription runs out
early; (5) they will accept generic brands of prescription
medication; (6) if daily function has not improved with
their prescription of pain medication, then the physician has
the right to taper the patient oﬀ the medication; (7) they
agree to submit to urine and blood screens to detect use
of nonprescribed medications and to verify the presence of
prescribed medications; (8) they agree to participate in all
aspects of treatment (e.g., physical therapy, psychotherapy,
and behavioral medicine); (9) they will only use one
pharmacy to ﬁll prescriptions, and agree to count pills from
the pharmacy; (10) they will be responsible in maintaining
their appointments. Patients should be encouraged to notify
their provider if an acute condition necessitates the need to
use additional pain medication.
The core elements to the controlled substances agree-
ment should be made clear so the patient knows exactly what
is expected of them. When the patient signs this agreement,
they are acknowledging their consent to the proposed
treatment plan and agree to adhere to the speciﬁc conditions
and responsibilities set by the clinic. It is imperative for all
individuals placed on chronic opioid therapy to read and
sign an opioid therapy agreement. In this way, patients can
be informed of their responsibilities and work to remain
compliant with their prescribed medication while avoiding
complications. Physicians should periodically request that
the patients complete an opioid compliance checklist, which6 Pain Research and Treatment
serves to remind patients of their responsibilities for using
opioids for pain (Appendix E).
Gourlay and colleagues created a rational approach to
opioid therapy for the treatment of chronic pain using
universal precautions [82]. This concept was borrowed
from infectious disease paradigms. This approach includes
a means of identifying and monitoring patients who may
be at risk for misusing physician-prescribed medication. In
order to properly assess if patients should be considered
for long-term opioid therapy, they suggest the following
recommended steps: (1) diagnosis with the appropriate
diﬀerential; (2) psychological assessment, including risk
potential for addictive disorder; (3) informed consent and
treatment agreement; (4) pain and function assessment; (5)
opioid therapy trial; (6) reassessment of pain, function, and
behavior (e.g., analgesia, activities of daily living, adverse
events); (7) periodic urine screens; (8) review of diagnosis
and comorbidities; (9) detailed documentation. A compre-
hensive pain management center may provide additional
assessment and input for patients who were referred by their
physicians. Some pain management specialists oﬀer a tri-
lateral agreement with the patient’s primary care physician.
Once it is determined that the patient has been compliant
and stable with their opioids, they can be referred back to
their primary care physician for management of their pain.
The pain specialist would provide a periodic reevaluation of
the patients if necessary.
10.Abuse-DeterrentOpioids
Several new opioid formulations that are designed to prevent
or deter the abuse of opioids are currently in development,
and two have been approved for marketing (morphine sul-
fate coformulated with naltrexone hydrochloride (Embeda)
and a new formulation of the extended-release oxycodone
(OxyContin)) (Appendix F). Abuse-deterrent formulations
are those that do not necessarily resist tampering but contain
substances that are designed to make the formulation less
attractive to abusers. Examples of these formulations are
Suboxone (buprenorphine coformulated with the opioid
antagonist naloxone), Embeda (an extended-release mor-
phine coformulated with the opioid antagonist naltrexone),
ELI-216 (an extended-release oxycodone coformulated with
naltrexone), and Acurox (an immediate-release oxycodone
coformulated with an aversive agent (niacin)). Tamper-
resistant formulations are not co-formulated with an antag-
onist or aversive agent but are designed to be very diﬃcult to
crush or dissolve and thus would prevent chewing, snorting,
or injecting the medication. Examples include Remoxy,
COL-003, TQ-1017, and the reformulationof OxyContin, all
of which are extended-release formulations of oxycodone.
There are still many issues that are yet to be addressed
about their integration into clinical practice and their true
abuse liability in real-world scenarios. The cost of these
new preparations will likely present a challenge, particularly
for insurance carriers and pharmacy managers attempting
to justify their use based on cost-beneﬁt analyses. The
only substantial real-world experience with these types of
formulations is with Suboxone even though this combina-
tion of buprenorphine and naltrexone is not approved for
the treatment of pain. One study suggested dose escalation
is typically greater with pure formula opioids and is not
associated with the clinical severity of low back pain, or pain
resulting from surgery [83].
Another study suggested that introduction of Suboxone
did not reduce buprenorphine injection in Malaysian sub-
stance abusers [84]. Recent ﬁndings suggest that Suboxone,
which is used by 170,000 people in the US on a daily basis,
is still occasionally crushed and injected by abusers (http://
www.choosehelp.com/news/getting-high-on-suboxone-the-
fda-says-its-happening-ex-nida-director-blames-doctors
.html, Accessed April 23, 2010). Yet even with a certain level
of abuse, Suboxone therapy is still considered the safest
treatment for opioid addiction. One double-blind study
compared buprenorphine transdermal system to placebo
and found this treatment to be eﬀective for the management
of moderate to severe chronic low back pain for patients
who have previously received opioids for their pain [85].
The Suboxone example suggests that abuse-deterrent or
tamper-resistant formulations are not likely to completely
prevent or deter abuse but that the reductions in abuse they
provide may be an important incremental step towards safer
treatments and safer communities.
11. Interventions for High-Risk Patients
Chronic pain patients who show aberrant drug-related
behavior often are discontinued from treatment when they
are noncompliant with their use of opioids for pain. A ran-
domized trial of patients prescribed opioids for noncancer
back pain who showed risk potential for or demonstration
of opioid misuse was conducted to see if close monitoring
and cognitive behavioral substance misuse counseling could
increase overall compliance with opioids [86]. Forty two
patients meeting criteria for high risk for opioid misuse
were randomized to either standard control (High-Risk
Control; N = 21) or experimental compliance treatment
consisting of monthly urine screens, compliance checklists,
and individual and group motivational counseling (High-
Risk Experimental; N = 21). Twenty patients who met
criteria indicating low potential for misuse were recruited to
a low-risk control group (Low-Risk Control). Patients were
followed for six months and completed pre- and poststudy
questionnaires and monthly electronic diaries. Outcomes
consisted of the percent with a positive Drug Misuse Index
(DMI), which was a composite score of self-reported drug
misuse (Prescription Drug Use Questionnaire), physician-
reportedabusebehavior(AddictionBehaviorChecklist),and
abnormal urine toxicology results. After six months, signif-
icant diﬀerences were found between groups with 73.7%
of the High-Risk Control patients demonstrating positive
scores on the DMI compared with 26.3% from the High-
Risk Experimental group and 25.0% from the Low-Risk
Controls (P<0.05). The results of this study demonstrate
support for the beneﬁts of a brief behavioral intervention in
the management of opioid compliance among chronic back
pain patients at high-risk for prescription opioid misuse. AtPain Research and Treatment 7
followup, none of the subjects was dismissed from the clinic
due to aberrant drug behavior, which was possibly a partial
eﬀect of the attention from being in a study and completing
monthly electronic diaries. Overall, this study demonstrated
apositi v eeﬀectofimprovingopioidcompliance,particularly
among those patients at high risk for misuse of opioids.
The results of this study are encouraging and suggest
that compliance training and very careful monitoring of
those patients determined to be at high risk for opioid
misuse can be incorporated as part of an anesthesia-based
multidisciplinary pain program to help improve compliance
with opioids and to reduce the number of those individuals
who are discharged from treatment because of aberrant
drug-related behavior. Although further research is needed,
this trial demonstrates that substantial improvement in
compliance with prescription opioids for many high-risk
pain patients is possible within a pain management center.
12. FutureConsiderations
As the world population ages and life expectancy increases,
greater attention will be given to managing medical comor-
bidities, including chronic back pain. The practice of pain
management will likely be changing within the next ﬁve
to ten years in a number of ways. First, opioids will
continue to be prescribed as a treatment for noncancer
back pain; however, a balance will likely be reached in
eﬀectively managing pain while also addressing the problems
with addiction, overdose, and death that these medications
can cause. In line with this change, new formulas of
abuse-deterrent opioids will continue to be developed and
greater attention will be given to educating physicians and
patients about proper dispensing, storing, and disposing
practices associated with the use of opioids. Also, healthcare
practitioners will be encouraged to have specialty training
andcertiﬁcationintheproperdispensingofopioids.Second,
software programs with interactive, dynamic education for
prescribers, pharmacists, and patients will continue to be
developed and made available to the general public. Greater
attention will also be given to outcome studies on the risk
factors that predict misuse of opioids.
Third, many other fruitful and exciting areas of study
will improve the way pain is managed. Genetics testing holds
much promise for the identiﬁcation of markers for poten-
tial opioid misuse. Our understanding of opioid-induced
hyperalgesia and craving within certain individuals will also
contribute to the identiﬁcation of sensitive markers for
opioid misuse. In particular, complex endogenous chemical
reactive systems that aﬀect tolerance and potential opioid
misuse will likely be reliably identiﬁed. Also, longitudinal
investigations on demographic factors such as gender, ethnic
origin, and personality predispositions that inﬂuence the
use of opioids will improve practice guidelines. Fourth,
additional studies on other treatments for back pain such
as the use of cannabinoids and their role in symptom
reduction could add to the current pain management
armamentarium. Also, the development of other delivery
systems such as topical preparations will oﬀer a wider array
of treatment options. The exciting area of nanotechnology
to deliver a drug to a particular area should also greatly
enhance treatment options. Finally, a greater understanding
of how an acute back pain problem develops into a chronic
pain syndrome with subtle eﬀects that this process has on
centralized mechanisms will open up interventions that are
currentlynotavailable.Althoughthemanagementofchronic
backpainwillalwaysbeachallenge,thefuturewilllikelyhold
answers for improved treatment for those who suﬀer with
chronic pain.
13. Conclusions
Comprehensiveassessmentandmonitoringisrecommended
for all patients who are on long-term opioid therapy for
chronic back pain. The close monitoring of patients who
are at greatest risk for misuse of their prescribed medication
should contain a treatment protocol that includes an opioid
agreement, regular urine toxicology screens, compliance
checklists, pill counts, and, if indicated, motivational coun-
seling. Careful monitoring and use of abuse-deterrent opi-
oids will hopefully decrease the abuse potential of prescribed
opioids; however, risk of opioid misuse and addiction will
remain, and close attention to screening and documentation
of treatment outcomes will continue to be the gold standard
of opioid therapy.
Appendices
A.Terminology DeﬁnitionsRelatedto
SubstanceUse Disorders
Substance Misuse. The use of any drug in a manner other
than how it is indicated or prescribed.
Substance Abuse. The use of any substance when such use
is unlawful, or when such use is detrimental to the user or
others.
Addiction. A primary, chronic, neurobiologic disease that
is characterized by behaviors that include one of more of
the following: impaired control over drug use, compulsive
use, continued use despite harm, and craving. Addiction is
generally understood to be a chronic condition from which
recovery is possible; however, the underlying neurobiologic
dysfunction, once manifested, is believed to persist.
PhysicalDependence. Astateofadaptationthatismanifested
by a drug class-speciﬁc withdrawal syndrome that can be
produced by abrupt cessation, rapid dose reduction, or
decreasing blood levels of the drug and/or by administration
of an antagonist.
Tolerance. A state of adaptation in which exposure to a drug
induces changes that result in diminution of one or more of
the drug’s eﬀects over time.8 Pain Research and Treatment
Aberrant Drug-Related Behavior. Behavior suggestive of a
substance abuse and/or addiction disorder. Examples are
selling prescription drugs, prescription forgery, stealing or
“borrowing” drugs from others, injecting oral formulations,
obtaining prescription drugs from nonmedical sources,
multiple episodes of prescription “loss,” repeatedly seeking
prescriptionsfromotherclinicians,evidenceofdeterioration
in function (work, home, family), and repeated resistance to
change therapy despite evidence of physical and psychologi-
cal problems.
Pseudoaddiction. An iatrogenic misinterpretation caused by
undertreated pain that is identiﬁed by the clinician as
inappropriate drug seeking behavior. Misuse behavior ceases
when adequate pain relief is provided. This is not a diagnosis
but rather a description of a clinical interaction.
B. List of OpioidRisk ScreeningTools
(i) Screener and Opioid Assessment for Patients in Pain-
Revised (SOAPP-R).
(ii) Current Opioid Misuse Measure (COMM).
(iii) Opioid Risk Tool (ORT).
(iv) Diagnosis, Intractability, Risk, and Eﬃcacy (DIRE).
(v) Screening Instrument for Substance Abuse Potential
(SISAP).
(vi) The Pain Assessment and Documentation Tool
(PADT).
C. Risk Factors for Opioid Misuse
(i) Family history of substance abuse.
(ii) Personal history of substance abuse.
(iii) Young age.
(iv) History of criminal activity and/or legal problems
including DUIs.
(v) Regular contact with high-risk people or high-risk
environments.
(vi) Problems with past employers, family members, and
friends (mental disorder).
(vii) Risk taking or thrill seeking behavior.
(viii) Heavy tobacco use.
(ix) History of severe depression or anxiety.
(x) Psychosocial stressors.
(xi) Prior drug and/or alcohol rehabilitation.
D.Example of a Controlled
SubstanceAgreement
This agreement relates to my use of controlled substances for
chronic pain prescribed by a physician. I have been informed
and understand the policies regarding the use of controlled
substances. I understand that I will be provided controlled
substances while actively participating in this program only
if I adhere to the following conditions:
(1) I will use the substances only as directed by my
physician.
(2) I will not expect to receive replacement medications
for any medications that I have lost or have been
stolen. A police report must be produced for any
consideration of replacement of any lost or stolen
medication.
(3) I will receive controlled substances only from one
physician. Information that I have obtained con-
trolled substances from another physician without
prior knowledge will lead to discontinuation of
treatment.
(4) I will not expect to receive additional medication
prior to the time of my next scheduled reﬁll, even if
my prescription runs out.
(5) I will accept generic brands of my prescription
medication, where determined appropriate by my
physician.
(6) If it appears to the physician that there are no
demonstrable beneﬁts to my daily function or quality
of life from the controlled substance, I will gradually
taper my medication as directed by my prescribing
physician.
(7) I agree to submit to urine and blood screens to detect
the use of nonprescribed controlled medications
(including “street” drugs) and verify the presence of
my prescribed medications at any time.
(8) Irecognizethatmychronicpainrepresentsacomplex
problem, which may beneﬁt from physical therapy,
psychotherapy, and behavioral medicine strategies.
I also recognize that my active participation in the
management of my pain is extremely important.
I agree to actively participate in all aspects of my
treatment to maximize functioning and improve
coping with my condition.
(9) I agree to schedule and keep scheduled follow-up
appointments with my physician at recommended
intervals. I understand that failure to keep appoint-
ments may lead to discontinuation of treatment.
(10) I am responsible for keeping track of the amount
of medication that I have left and to plan ahead for
arranging the reﬁll of my prescriptions in a timely
manner so I will not run out of medications.
( 1 1 ) Ia g r e et ou s eo n ep h a r m a c yf o rﬁ l l i n ga l lm y
prescriptions except in case of emergency.
(12) I will agree to count my pills that I receive from
pharmacy and will ensure that the correct amount isPain Research and Treatment 9
received.IunderstandthatIwillnotexpectmyphysi-
cian to cover me for any shortage of medication. Any
shortage found must be discussed immediately upon
my receiving the prescription with the pharmacist.
(13) If I violate any of the above conditions, my obtaining
prescriptions and/or treatment may be terminated.
(14) If I violate any of the above conditions and the
violation involves obtaining controlled substances,or
anyprescription,formypainconditionfromanother
individual, or, if I engage in any illegal activity such
as altering a prescription, I understand that the
incidentmaybereportedbymyphysician.Asdeemed
appropriate for the violation, my physician may
report my violations to other physicians caring for
me, local medical facilities, pharmacies, local police
departments, and/or Drug Enforcement Agencies.
(15) I can designate up to two other people to pick up
my prescriptions. I understand that I must notify
my physician in advance each and every time a
prescription is reﬁlled if an alternate person will be
picking up the prescription. Failure to do this could
result in the prescription not being released. The
names of these people must be entered at the bottom
of this contract.
(16) This Controlled Substances Contract will become
part of my permanent medical record.
This agreement will supersede all other agreements.
By signing below, I indicate that I understand and agree
toallthetermsoftheaboveagreement.Ihavereceivedacopy
of this for my own records.
Patient:
Date and Time:
Physician:
Date and Time:
Names of the people that I designated to pick up my
prescriptions
#1
#2
E.Opioid Compliance Checklist
Print name:
Date:
Please answer the following questions as honestly as
possible:
Over the past month have you:
(1) Taken your opioid medication other than the way
they were prescribed? Yes No
(2) Used more than one pharmacy to ﬁll your opioid
prescriptions? Yes No
(3) Received opioid prescriptions from more than one
provider? Yes No
(4) Lost or misplaced your opioid medication?
Yes No
(5) Run out of your pain medication early? Yes No
(6) Missed any scheduled medical appointments?
Yes No
(7) Borrowed opioid medication from others?
Yes No
(8) Used any illegal or unauthorized substances?
Yes No
(9) Taken the highest possible degree of care of your
prescription medication? Yes No
(10) Taken any unauthorized substance that might be
found in your urine? Yes No
(11) Been involved in any activity that may be dangerous
t oy o uo rs o m e o n ee l s ei fy o uf e l td r o w s yo rw e r en o t
clear thinking? Yes No
(12) Been completely honest about your personal drug
use? Yes No
Please explain anything further below. Thank you.
Signed:
Date:
F.Abuse-DeterrentOpioids
(i) Current name: Remoxy.
Active Drug: Oxycodone (extended-release).
Type of Formulation: Gelatin capsule containing
highly viscous liquid.
Manufacturer: Pain Therapeutics; Pﬁzer (formerly
King Pharmaceutical).
(ii) Current name: COL-003.
Active Drug: Oxycodone (extended-release).
Type of Formulation: Multiparticulate matrix with
particles in waxy excipient base.
Manufacturer: Collegium Pharmaceutical.
(iii) Current name: ELI-216.
Active Drug: Oxycodone (extended-release).
Type of Formulation: Capsule containing separate
oxycodone and naltrexone pellets.
Manufacturer: Elite Pharmaceuticals.
(iv) Currentname:Unknown(reformulationofOxyCon-
tin).
Active Drug: Oxycodone (extended-release).10 Pain Research and Treatment
Type of Formulation: Hard polymer that transforms
into a viscous gel with hydration.
Manufacturer: Purdue Pharma.
(v) Current name: Embeda (ALO-01).
Active Drug: Morphine (extended-release)
Type of Formulation: Pellets of morphine surround-
ing an inner core of naltrexone.
Manufacturer: Pﬁzer (formerly King Pharmaceuti-
cal).
(vi) Current name: TQ-1017.
Active Drug: Tramadol (extended-release).
Type of Formulation: Transforms into viscous sub-
stance in the presence of solvents.
Manufacturer: TheraQuest Biosciences.
(vii) Current name: Acurox.
Active Drug: Oxycodone (immediate-release).
Type of Formulation: Coformulated with subthera-
peutic doses of niacin.
Manufacturer: Acura Pharmaceuticals, Pﬁzer (for-
mer King Pharmaceutical).
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